Burning Rock Dx(US:BNR) Jin Rong Jie·2025-08-04 14:22Core Viewpoint - The company, Burning Stone Medical (BNR), has shown a positive stock performance with a 5.11% increase, reaching $5.96 per share, and a total market capitalization of approximately $64.17 million as of August 4 [1]. Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94% [1]. - The company experienced a net loss attributable to shareholders of 13.5 million RMB, which represents a significant year-on-year improvement of 88.89% [1]. Upcoming Events - Burning Stone Medical is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual release date subject to company announcements [1]. Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company's business and research directions include: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1]. Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2]. - The company's laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2]. - The California laboratory of the company has also received CLIA and CAP laboratory quality system certifications [2].